معرفی
Dr David Bulmer is an Associate Professor in the Department of Pharmacology at the University of Cambridge, School of Biological Sciences. He is also Bye Fellow at Wolfson College and was previously a Visiting Lecturer in Neuroscience at Queen Mary University of London.
- Current Position: Associate Professor, Department of Pharmacology, University of Cambridge
- Previous Employment: Lecturer in Neurogastroenterology, Queen Mary University of London (2009-2017)
- Industry Experience: Neuroscience & Gastrointestinal Centre of Excellence in Drug Discovery at GlaxoSmithKline
- Education: BSc in Pharmacology from University of Manchester and PhD in Autonomic Neuroscience from University College London
Dr Bulmer's research focuses on understanding the causes of pain in gastrointestinal disorders, particularly Inflammatory Bowel Disease (IBD) and Irritable Bowel Syndrome (IBS). His work examines how mediators released from the gut sensitize pain-sensing nerves (nociceptors), leading to the perception of pain in the brain. His lab has identified key roles for voltage-gated sodium channels (NaV1.9) and Matrix Metalloproteinases in activating visceral nociceptors in IBD. His research combines electrophysiological, imaging and sequencing approaches with tissue samples from well-phenotyped patient cohorts.
His recent publications span several key areas including the role of ion channels in visceral pain (NaV1.9, KV7, TRPV4), neuro-immunological interactions in pain (IL-13, IL-17, TNFα, angiotensin II), gut-brain axis signaling (ATP, glutamate), and development of novel bioelectronic devices for studying gut function. His work has strong translational components, often bridging fundamental discoveries with potential clinical applications.
Dr Bulmer collaborates with both academic institutions and pharmaceutical companies including Astra Zeneca, Sosei-Heptares and GlaxoSmithKline. His research is supported by funding from Crohn's and Colitis UK, Crohn's and Colitis Foundation, BBSRC, MRC, Takeda Pharmaceuticals, Pfizer, and the Pain Relief Foundation.
